A Phase I Study and Pharmacological Trial of Once Weekly Aminoflavone Prodrug (AFP464) Administered 3 Out of Every 4 Weeks in Solid Tumor Patients.
Phase of Trial: Phase I
Latest Information Update: 22 Apr 2014
At a glance
- Drugs AFP 464 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Jul 2012 Planned end date changed from 1 May 2007 to 1 Jan 2100 as reported by ClinicalTrials.gov.